Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Lebrikizumab (Ebglyss) is a recombinant human IgG4 monoclonal antibody ...

The United States Food and Drug Administration reported changes in drug approvals, warnings, and indications for products for dermatologic use in 2024. Throughout 2024, the Food and Drug ...

随着礼来重磅减重药物替尔泊肽斩获治疗睡眠呼吸障碍的适应症，本年度FDA的监管批准工作算是告一段落。 FDA官网显示，2024年共批准50款新药（FDA ...

FDA's approval of eladocagene exuparvovec-tneq (Kebilidi) makes that product the first FDA-approved gene therapy for treating AADC deficiency. CHMP has granted Eisai Europe and Biogen a positive ...

After trying many topical steroids throughout the years he finally found relief with Ebglyss, a new treatment which helped reduce the itch with which he was struggling. Audra, a 4-year-old with ...

Adbry (tralokinumab-ldrm) was approved by the FDA in 2021. It is available for people 12 and older with moderate to severe atopic dermatitis. Ebglyss (lebrikizumab-lbkz) was approved by the FDA in ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce... ByInvesting.com • 25 Oct ...